We show that this requires activation of the PI3K pathway and is dependent on the PI3K subunit p110δ, a molecule currently being targeted in the setting of several B cell malignancies (CLL, non-Hodgkin lymphoma) (18). This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.